The PI3K Inhibitor Copanlisib Synergizes With Sorafenib to Induce Cell Death in Hepatocellular Carcinoma

Cell Death Discovery - United Kingdom
doi 10.1038/s41420-019-0165-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Combinatorial Screening of the Pi3k Inhibitor Copanlisib in T Cell Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Sorafenib in Hepatocellular Carcinoma

Clinical Medicine. Therapeutics
2009English

Selinexor Synergizes With Dexamethasone to Repress mTORC1 Signaling and Induce Multiple Myeloma Cell Death

Oncotarget
Oncology
2018English

Copanlisib for Treatment of B-Cell Malignancies: The Development of a PI3K Inhibitor With Considerable Differences to Idelalisib

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2018English

Next-Generation Proteasome Inhibitor Oprozomib Synergizes With Modulators of the Unfolded Protein Response to Suppress Hepatocellular Carcinoma

Oncotarget
Oncology
2016English

Topotecan Synergizes With CHEK1 (CHK1) Inhibitor to Induce Apoptosis in Ovarian Cancer Cells

BMC Cancer
Cancer ResearchOncologyGenetics
2015English

Sorafenib vs Nivolumab in Patients With Hepatocellular Carcinoma

Journal of Liver Research, Disorders & Therapy
2017English

Antitumor Effect of Sorafenib and mTOR Inhibitor in Liver Transplantation Recipients With Hepatocellular Carcinoma Recurrence

Liver Transplantation
HepatologyTransplantationSurgery
2018English

MicroRNA‑223 Promotes Hepatocellular Carcinoma Cell Resistance to Sorafenib by Targeting FBW7

Oncology Reports
MedicineCancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy